Nishi Shah, MD
Ophthalmology · Phoenix, AZNPI 1962881698
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $55,073 of the $91,731 with a category attached, or 60.0%. Dompe US, Inc. accounts for 94.7% of it on its own, with 22 other manufacturers making up the rest. Among ophthalmology clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 354 payments — averaging $259.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dompe US, Inc.$87K
- Biotissue Holdings Inc.$1K
- Alcon$808
- Rxsight Inc$636
- Sun Pharmaceutical Industries Inc.$555
- Glaukos Corporation$410
- plus $1K from 17 others
What the payments were for
- Consulting fees$2,5003%
- Speaking & faculty fees$55,07360%
- Travel & lodging$26,23629%
- Food & beverage$7,9219%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Dompe US, Inc. | 236 | $86,846 |
| Biotissue Holdings Inc. | 28 | $1,055 |
| Alcon | 18 | $808 |
| Rxsight Inc | 8 | $636 |
| Sun Pharmaceutical Industries Inc. | 17 | $555 |
| Glaukos Corporation | 3 | $410 |
| Tarsus Pharmaceuticals, Inc. | 7 | $270 |
| Mallinckrodt Hospital Products Inc. | 8 | $219 |
| AbbVie | 1 | $147 |
| Bausch & Lomb Americas Inc. | 7 | $140 |
| Harrow Eye, LLC | 5 | $114 |
| Genentech USA, Inc. | 1 | $81 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $78 |
| Carl Zeiss Meditec USA, Inc. | 1 | $74 |
| Heidelberg Engineering, Inc. | 1 | $68 |
| ANI Pharmaceuticals, Inc. | 2 | $44 |
| Amgen | 2 | $38 |
| Thea Pharma Inc. | 2 | $35 |
| Apellis Pharmaceuticals, Inc. | 1 | $34 |
| Rayner Intraocular Lenses Limited | 1 | $27 |
| Oyster Point Pharma, Inc. | 1 | $21 |
| Kala Pharmaceuticals, Inc. | 1 | $17 |
| Taiho Oncology, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Oxervate$68,167
- RXSIGHT CONTACT LENS$400
- RXSIGHT INJECTOR CARTRIDGE$400
- RXSIGHT INJECTOR HANDPIECE$400
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$400
- LIGHT ADJUSTABLE LENS (LAL)$276
- CEQUA$247
- iDoseTR$155
- Clareon$141
- XDEMVY$136
- Clareon PanOptix Pro$132
- RXSIGHT LIGHT ADJUSTABLE LENS (RXLAL)$124
- Prokera$123
- AmnioGraft$123
How this compares
$91,731 in reported general payments places this provider in the 95th percentile of 310 ophthalmology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxervateCenegermin-Bkbj | 69 | $2,063,123 |
| RestasisCyclosporine | 138 | $114,339 |
| CequaCyclosporine | 69 | $52,291 |
| Pred FortePrednisolone Acetate | 175 | $35,754 |
| Cyclosporine | 63 | $31,258 |
| Prednisolone Acetate | 642 | $20,791 |
| MoxifloxacinMoxifloxacin Hcl | 621 | $15,155 |
| Loteprednol Etabonate | 99 | $14,427 |
| Difluprednate | 73 | $7,603 |
| Ketorolac Tromethamine | 299 | $6,269 |
| CombiganBrimonidine Tartrate/Timolol | 15 | $3,738 |
| ValacyclovirValacyclovir Hcl | 45 | $3,284 |
| Acyclovir | 116 | $2,847 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 22 | $2,270 |
| Fluorometholone | 22 | $2,055 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Dompe US, Inc.Oxervate | $86,846 | $2,063,12369 claims |
| AbbVieRestasis, Combigan | $147 | $118,077153 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $555 | $52,29169 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 310 ophthalmology providers in Arizona.
Other ophthalmology in Phoenix
- Pravin DugelPhoenix$176K
- Karim JamalPhoenix$72K
- Benjamin HellerPhoenix$41K
- Neal PalejwalaPhoenix$33K
- Joshua DuncanPhoenix$30K
- Sachin MehtaPhoenix$23K
- Daniel ChurginPhoenix$15K
- John CasonPhoenix$14K
- Sujit IttyPhoenix$14K
- Elahhe AfkhamnejadPhoenix$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.